Terazosin hydrochloride dihydrate

Overview

Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment.

Application

Products | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Depression | Products > Disease Areas > Pain | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Hypertension | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Metabolic Disease | Products > Research Areas > Endocrinology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Adrenergic Receptor

Product Information

• Catalog No.: HY-B0371A
• CAS No.: 70024-40-7
• Molecular Formula: C19H30ClN5O6
• Molecular Weight: 459.92
• Purity: 99.92%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.5 mg/mL (5.44 mM); Clear solution
• Availability: In-stock

Source

Original product source